Integrated tumor-targeted LNP development services for oncology-focused RNA and small-molecule delivery programs.
Tumor-targeted lipid nanoparticle (LNP) development is becoming a high-priority strategy for drug developers seeking to improve payload localization, increase cellular uptake in diseased tissue, and reduce non-productive distribution. In oncology programs, the challenge is rarely limited to encapsulation alone. Successful systems must balance lipid composition, targeting ligand presentation, colloidal stability, payload protection, endosomal escape behavior, and in vivo tumor accumulation within one coherent design framework. BOC Sciences provides specialized tumor-targeted LNP development services to support early discovery, formulation screening, and candidate optimization for researchers working on mRNA, siRNA, plasmid DNA, peptides, proteins, and selected small-molecule payloads. Our team helps clients build rational LNP systems for tumor-oriented delivery by integrating ligand engineering, formulation optimization, physicochemical characterization, and functional evaluation into one development workflow.
Full-spectrum tumor-targeted LNP development and delivery processWe provide a development framework for researchers who need more than a generic LNP formulation. Our services are designed to address the key variables that determine whether an LNP reaches tumor-associated cells efficiently and performs as intended after internalization.
We begin with a project-specific design strategy built around tumor indication, payload class, route of administration, and intended cellular destination.
Active tumor targeting depends on how ligands are selected, presented, and retained on the particle surface without undermining formulation integrity.
Tumor-targeted performance starts with a robust LNP core. We optimize ionizable lipid, helper lipid, sterol, and PEG-lipid ratios to support encapsulation efficiency, particle uniformity, and delivery behavior.
Different payload classes create different development bottlenecks. We adapt encapsulation strategies to the physicochemical demands of each cargo.
We help determine whether the targeting strategy translates into meaningful in vitro and in vivo behavior rather than only improved particle appearance.
Development decisions depend on reliable analytics. We integrate formulation data with physicochemical and performance readouts to refine the candidate design.
Tumor-targeted LNP development requires more than attaching a ligand to a standard formulation. We use a multi-parameter strategy to improve the probability of tumor localization, cellular entry, and payload function.
Build targeted LNP candidates with integrated support spanning ligand design, formulation optimization, characterization, and tumor-oriented performance evaluation.
Our tumor-targeted LNP development services support oncology research across a wide range of solid tumor types. We tailor targeting ligand design, surface engineering, and delivery strategy according to the biological features, receptor landscape, and microenvironmental characteristics of each tumor indication.
| Tumor Type | Targeting Strategy |
|---|---|
| Hepatocellular Carcinoma (HCC) | LNPs can be engineered to improve targeting of hepatocellular carcinoma through recognition of liver tumor-associated receptors such as glypican-related or asialoglycoprotein receptor-linked pathways, combined with surface modifications that enhance uptake by malignant hepatocytes while reducing non-specific distribution. |
| Non-small Cell Lung Cancer (NSCLC) | Targeting strategies for NSCLC commonly involve ligand-mediated recognition of receptors overexpressed on lung tumor cells, such as EGFR-related or integrin-associated targets, together with particle size and surface property optimization to improve tumor localization and cellular internalization. |
| Breast Cancer | Breast cancer-targeted LNPs may be designed through surface ligands that recognize tumor-associated markers such as HER2, folate receptor, or transferrin-related pathways, helping promote selective interaction with breast tumor cells and improve intracellular payload delivery. |
| Colorectal Cancer | For colorectal cancer, LNP targeting can be enhanced by using ligands directed toward receptors or adhesion molecules enriched in tumor tissues, alongside formulation strategies that support penetration into colorectal tumor environments and efficient uptake by malignant cells. |
| Pancreatic Cancer | Pancreatic tumor targeting often requires a combination of receptor-recognition design and microenvironment-adapted delivery logic, including ligands for mesothelin-related or integrin-mediated uptake pathways, as well as surface engineering to improve performance in dense stromal tumor regions. |
Oncology-focused LNP programs often fail because one design variable improves targeting while another undermines stability or payload function. We help resolve the following bottlenecks:
✔ Weak Tumor Accumulation
Standard LNPs may show acceptable encapsulation but insufficient localization within solid tumors. We optimize size, surface architecture, and targeting strategy to improve tumor-oriented distribution performance.
✔ Poor Ligand Presentation
A targeting ligand can be present on paper yet function poorly in practice because of unfavorable orientation, shielding, or unstable conjugation. We evaluate ligand format, linker design, and surface density to improve receptor accessibility.
✔ Liver-Dominant Off-Target Distribution
Many LNP systems naturally favor hepatic uptake. We support formulation redesign efforts intended to shift performance toward extrahepatic, tumor-relevant delivery behavior.
✔ Endosomal Escape Limitations
A particle may bind and internalize efficiently while still failing to release its payload into the cytosol. We correlate lipid composition with functional intracellular delivery outcomes rather than uptake alone.
✔ Instability After Surface Functionalization
Adding a targeting layer can change particle size, dispersity, and colloidal behavior. We assess how conjugation affects formulation robustness and adjust composition to preserve usable particle properties.
✔ Difficult Screening Decisions
Projects often generate many candidate formulations with fragmented data. We integrate characterization and biological readouts to help identify which candidates truly merit further development.
We review tumor type, intended target cell population, payload class, and experimental objective to define a feasible targeting and formulation strategy.
Candidate LNP compositions and ligand incorporation approaches are designed and screened to establish workable particle architectures for the program.
Targeted and control formulations are evaluated through analytical characterization and tumor-relevant biological testing to identify meaningful structure-function relationships.
We provide data-supported optimization recommendations and a structured report summarizing formulation composition, targeting strategy, analytical outcomes, and development insights.
Client Need: A client developing an siRNA oncology program for non-small cell lung cancer (NSCLC) needed a tumor-targeted LNP that could improve delivery to EGFR-positive tumor cells and outperform a non-targeted benchmark in functional gene silencing.
Project Challenge: After ligand modification, the formulation showed larger particle size, reduced colloidal stability, and no clear distinction between EGFR-mediated uptake and background internalization. The client also needed to determine whether the performance limitation arose from ligand presentation or from the LNP core formulation itself.
Our Solution: BOC Sciences established a focused optimization workflow for NSCLC-targeted delivery, covering ligand format, linker design, surface incorporation strategy, and lipid composition. We compared targeted and non-targeted controls, screened multiple ligand densities, and optimized ionizable lipid/helper lipid/PEG-lipid ratios to restore particle uniformity after surface functionalization. Uptake studies in EGFR-relevant NSCLC cell models were then directly correlated with gene silencing readouts, enabling identification of formulations that achieved both stronger tumor-targeting behavior and productive intracellular siRNA delivery.
Result: The optimized candidate demonstrated a clearer EGFR-dependent uptake profile, improved formulation consistency, and stronger silencing activity than the initial system, providing the client with a more reliable LNP lead for NSCLC-focused research.
Client Need: A research team developing an mRNA oncology platform for HER2-positive breast cancer wanted a tumor-focused LNP with stronger extrahepatic delivery potential while maintaining stable mRNA encapsulation and usable formulation quality.
Project Challenge: The baseline LNP provided good encapsulation, but its delivery profile was too generic for selective breast tumor targeting. Attempts to improve HER2-associated tumor interaction altered particle size, surface behavior, and overall formulation balance, making it difficult to determine which design variables were actually limiting performance.
Our Solution: BOC Sciences implemented an integrated design strategy combining formulation adjustment and surface engineering for breast cancer-directed delivery. We optimized ionizable lipid ratios, PEG-lipid content, and particle assembly conditions, then evaluated HER2-focused ligand-functionalized variants for size, PDI, surface behavior, encapsulation, and post-modification stability. These data were paired with uptake and expression-related studies in HER2-relevant breast cancer models so that targeted improvements could be distinguished from non-specific formulation effects.
Result: The project yielded an optimized breast cancer-focused mRNA LNP candidate with improved targeting logic, acceptable physicochemical quality, and a clearer path for further biological evaluation in HER2-positive tumor models.
Targeting-Oriented DesignWe develop LNPs around biological targeting goals rather than treating surface modification as a late-stage add-on.
Broad Payload CompatibilityOur workflows can be adapted for nucleic acids, proteins, peptides, and selected oncology small molecules requiring specialized LNP engineering.
Integrated AnalyticsWe connect formulation work with characterization, loading analysis, stability assessment, and biodistribution-oriented support to guide smarter iteration.
Application-Relevant DevelopmentOur service approach is aligned with tumor-directed delivery needs, including receptor targeting, microenvironment-oriented delivery, and extrahepatic optimization.
Flexible Internal Knowledge SupportClients can also explore related background content such as lipid nanoparticles in targeted delivery to cancer cells, cell-targeted nanoparticle delivery, and nanoparticles for cancer therapy for additional scientific context.
Because tumor-targeted LNPs cannot succeed by simply adding a ligand onto the surface of a conventional LNP. A truly effective system must simultaneously address multiple interdependent challenges, including particle size and dispersity control, ligand accessibility on the particle surface, stability in blood circulation, accumulation efficiency in tumor tissue, endosomal escape after cellular uptake, and effective release of the functional payload. Many systems show uptake signals in vitro but fail to translate into effective delivery in vivo. In development, BOC Sciences integrates ligand design, formulation screening, characterization, and functional validation to reduce the risk of imbalance caused by optimizing a single parameter.
Ligand selection should first focus on whether the target tumor or tumor microenvironment has receptors that are accessible, internalizable, and sufficiently differentially expressed—not just “highly expressed” as stated in literature. Ideal ligands must not only bind effectively but also consider spatial exposure after conjugation, linker length, surface density, and potential effects on LNP stability. Common options include peptides, aptamers, antibody fragments, carbohydrates, or small molecules. Development typically requires simultaneous screening of both ligand types and conjugation strategies to determine whether limitations arise from the target itself or from surface presentation.
It is not enough to observe particle uptake into cells. One must assess whether the uptake is receptor-dependent, superior to non-targeted controls, and whether it produces real functional outcomes. A reliable evaluation system typically includes comparisons between targeted and non-targeted groups, models with high vs. low receptor expression, competition inhibition studies, and correlation between uptake data and transfection or gene silencing results. If fluorescence uptake increases without corresponding improvements in expression, gene silencing, or other functional readouts, the targeting strategy cannot be considered truly effective. BOC Sciences evaluates uptake, distribution, and functional outcomes together to help identify approaches that appear effective but have limited real value.
Success is usually not determined by a single variable but by the combined effects of formulation structure and biological behavior. Key factors include the properties of ionizable lipids, the ratio of helper lipids to PEG-lipids, particle size range, surface charge, ligand density, payload type, and the accessibility of the tumor model itself. For RNA-based systems, endosomal escape efficiency is particularly critical, because even if LNPs achieve tumor accumulation and cellular uptake, poor cytosolic release will limit functional outcomes. Therefore, high-quality projects typically rely on systematic multi-parameter screening rather than optimizing only encapsulation efficiency or particle size.
Many LNP formulations may appear reasonable at the formulation level but still exhibit significant off-target distribution in vivo, especially accumulation in the liver. Biodistribution analysis helps determine whether targeting modifications truly alter delivery fate or merely improve in vitro uptake signals. For tumor applications, this step is critical not only for candidate selection but also for deciding whether further optimization of lipid composition, surface modification, or dosing strategy is needed. In service-based development projects, linking biodistribution with functional outcomes as early as possible helps reduce costly trial-and-error in later stages.
